Linnea is compliant with the new CBD monograph issued by the European pharmacopoeia
Linnea is proud to comply with the new CBD monograph issued by the European Pharmacopoeia. This monograph is applicable for medical prescriptions, pharmacy compounding, clinical trials, pharmaceutical development, and registrations.
The final draft was published in January 2024, and starting from July 2024, the rules and requirements detailed in the official text will be obligatory for all member states. Previous guidelines, such as the DAC monograph on CBD, will be superseded by a unified set of specifications.
These specifications include:
- Functionality-related characteristics: these are crucial for the quality of a medicinal product and the consistency of its manufacturing process.- Definition: the monograph specifies the content (98.0% to 102.0%) and clarifies that CBD is isolated from the Cannabis sativa L. plant.
- Characters:
- Appearance
- Solubility
- Identification:
- Infrared absorption spectrophotometry
- Specific optical rotation
- Storage
- Labelling
- Impurities: impurities are specified, cataloged, and acceptance criteria are provided for each.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance